These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23572162)

  • 1. Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer.
    Ferguson RD; Gallagher EJ; Cohen D; Tobin-Hess A; Alikhani N; Novosyadlyy R; Haddad N; Yakar S; LeRoith D
    Endocr Relat Cancer; 2013 Jun; 20(3):391-401. PubMed ID: 23572162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes.
    Ferguson RD; Novosyadlyy R; Fierz Y; Alikhani N; Sun H; Yakar S; Leroith D
    Breast Cancer Res; 2012 Jan; 14(1):R8. PubMed ID: 22226054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.
    Zelenko Z; Gallagher EJ; Antoniou IM; Sachdev D; Nayak A; Yee D; LeRoith D
    Endocr Relat Cancer; 2016 Sep; 23(9):747-58. PubMed ID: 27435064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression.
    Fierz Y; Novosyadlyy R; Vijayakumar A; Yakar S; LeRoith D
    Diabetes; 2010 Mar; 59(3):686-93. PubMed ID: 19959755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperinsulinemia Promotes Esophageal Cancer Development in a Surgically-Induced Duodeno-Esophageal Reflux Murine Model.
    Arcidiacono D; Dedja A; Giacometti C; Fassan M; Nucci D; Francia S; Fabris F; Zaramella A; Gallagher EJ; Cassaro M; Rugge M; LeRoith D; Alberti A; Realdon S
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression.
    Zelenko Z; Gallagher EJ; Tobin-Hess A; Belardi V; Rostoker R; Blank J; Dina Y; LeRoith D
    Oncogene; 2017 Mar; 36(10):1394-1403. PubMed ID: 27568979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
    Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammary tumor formation and metastasis evoked by a HER2 splice variant.
    Alajati A; Sausgruber N; Aceto N; Duss S; Sarret S; Voshol H; Bonenfant D; Bentires-Alj M
    Cancer Res; 2013 Sep; 73(17):5320-7. PubMed ID: 23867476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovariectomy is associated with metabolic impairments and enhanced mammary tumor growth in MKR mice.
    Ben-Shmuel S; Scheinman EJ; Rashed R; Orr ZS; Gallagher EJ; LeRoith D; Rostoker R
    J Endocrinol; 2015 Dec; 227(3):143-151. PubMed ID: 26383532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of Her2/Neu mammary tumor development in mda-7/IL-24 transgenic mice.
    Li YJ; Liu G; Xia L; Xiao X; Liu JC; Menezes ME; Das SK; Emdad L; Sarkar D; Fisher PB; Archer MC; Zacksenhaus E; Ben-David Y
    Oncotarget; 2015 Nov; 6(35):36943-54. PubMed ID: 26460950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.
    Xu C; Langenheim JF; Chen WY
    Breast Cancer Res Treat; 2012 Jul; 134(1):157-69. PubMed ID: 22270933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.
    Gallagher EJ; Alikhani N; Tobin-Hess A; Blank J; Buffin NJ; Zelenko Z; Tennagels N; Werner U; LeRoith D
    Diabetes; 2013 Oct; 62(10):3553-60. PubMed ID: 23835331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model.
    Rostoker R; Bitton-Worms K; Caspi A; Shen-Orr Z; LeRoith D
    Endocrinology; 2013 May; 154(5):1701-10. PubMed ID: 23515289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis.
    Chen H; Lee JS; Liang X; Zhang H; Zhu T; Zhang Z; Taylor ME; Zahnow C; Feigenbaum L; Rein A; Sukumar S
    Cancer Res; 2008 May; 68(10):3637-44. PubMed ID: 18463397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXB7 promotes malignant progression by activating the TGFβ signaling pathway.
    Liu S; Jin K; Hui Y; Fu J; Jie C; Feng S; Reisman D; Wang Q; Fan D; Sukumar S; Chen H
    Cancer Res; 2015 Feb; 75(4):709-19. PubMed ID: 25542862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
    Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
    Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
    Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
    Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly specific role of the insulin receptor in breast cancer progression.
    Rostoker R; Abelson S; Bitton-Worms K; Genkin I; Ben-Shmuel S; Dakwar M; Orr ZS; Caspi A; Tzukerman M; LeRoith D
    Endocr Relat Cancer; 2015 Apr; 22(2):145-57. PubMed ID: 25694511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic overexpression of the miR-200b/200a/429 cluster prevents mammary tumor initiation in Neu/Erbb2 transgenic mice.
    Watson KL; Moorehead RA
    Int J Cancer; 2024 Oct; ():. PubMed ID: 39369448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.